Ocular Therapeutix is progressing its small molecule drug AXPAXLI (OTX-TKI) for wet age-related macular degeneration (wet-AMD), showing superior vision maintenance over EYLEA in trials. The company plans to submit a New Drug Application (NDA) and expects interim safety data by Q4 2026, with primary endpoint results anticipated in Q1 2028. Additional studies are exploring extended dosing and new indications, including early positive results in diabetic retinopathy. This progress supports maintaining a "Buy" rating on the stock due to promising clinical data and regulatory alignment.
Ocular Therapeutix's NDA submission plans and drug development progress provide context for readers. For those following health-sector stocks on Pluang, 81 of 150 US stocks rose and 68 fell as of Nov 14, 2026 03:21 WIB. Notable movers include ALNY at USD 164.69 with a 5.13% increase and 100% buy order activity, ADMA up 4.95% at USD 13.89, and SMMT down 4.34% at USD 14.42 with 88% buy activity.
ArrowMark Financial Corp. announced a monthly cash distribution of $0.15 per share for November 2026, payable on November 30 to shareholders of record as of November 23. This distribution reflects the company's ongoing commitment to provide current i...
Liberty Defense Holdings clarified details of its credit facility and term loan with Parabilis, originally announced in 2024. The company’s subsidiary received a $1.8 million term loan and a $2.5 million revolving credit facility, both secured by sub...
Stardust Power announced a $2.8 million net loss for Q3 2026, an improvement from $4.5 million last year, driven by lower administrative costs and warrant value changes. The company is progressing its lithium refinery project in Muskogee, Oklahoma, d...
byNordic Acquisition Corporation, a special purpose acquisition company, has extended its deadline to complete a business combination by one month, moving it from November 12, 2026, to December 12, 2026. This is the fourth of up to twelve possible on...
Texas Pacific Land Corporation reported a high Return on Invested Capital (ROIC) of 30.81%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 7.73%. This strong performance results in the highest ROIC-to-WACC ratio of 3.98 among...
